Session

Progress in liver disease biomarkers

CIRCULATORY HSA-MIR-339-5P IS ASSOCIATED WITH LATER DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE IN THE PROSPECTIVE YOUNG FINNS STUDY
CIRCULATORY HSA-MIR-339-5P IS ASSOCIATED WITH LATER DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE IN THE PROSPECTIVE YOUNG FINNS STUDY

Progress in liver disease biomarkers  et al.

VALIDATION OF CACLD RISK MODEL FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) IN NAFLD PATIENTS
VALIDATION OF CACLD RISK MODEL FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) IN NAFLD PATIENTS

Progress in liver disease biomarkers  et al.

PROTEOMICS TO DISCRIMINATE SIGNIFICANT FIBROSIS IN TWO INDEPENDENT COHORTS OF BIOPSY-PROVEN NAFLD
PROTEOMICS TO DISCRIMINATE SIGNIFICANT FIBROSIS IN TWO INDEPENDENT COHORTS OF BIOPSY-PROVEN NAFLD

Progress in liver disease biomarkers  et al.

THE VALUE OF SERUM PRONEUROTENSIN AS A PREDICTOR OF CARDIOVASCULAR RISK IN NAFLD PATIENTS
THE VALUE OF SERUM PRONEUROTENSIN AS A PREDICTOR OF CARDIOVASCULAR RISK IN NAFLD PATIENTS

Progress in liver disease biomarkers  et al.

VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE
VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE

Progress in liver disease biomarkers  et al.

VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE
VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE

VALIDATION OF CACLD RISK MODEL FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) IN NAFLD PATIENTS
VALIDATION OF CACLD RISK MODEL FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) IN NAFLD PATIENTS

THE VALUE OF SERUM PRONEUROTENSIN AS A PREDICTOR OF CARDIOVASCULAR RISK IN NAFLD PATIENTS
THE VALUE OF SERUM PRONEUROTENSIN AS A PREDICTOR OF CARDIOVASCULAR RISK IN NAFLD PATIENTS

CIRCULATORY HSA-MIR-339-5P IS ASSOCIATED WITH LATER DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE IN THE PROSPECTIVE YOUNG FINNS STUDY
CIRCULATORY HSA-MIR-339-5P IS ASSOCIATED WITH LATER DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE IN THE PROSPECTIVE YOUNG FINNS STUDY

PROTEOMICS TO DISCRIMINATE SIGNIFICANT FIBROSIS IN TWO INDEPENDENT COHORTS OF BIOPSY-PROVEN NAFLD
PROTEOMICS TO DISCRIMINATE SIGNIFICANT FIBROSIS IN TWO INDEPENDENT COHORTS OF BIOPSY-PROVEN NAFLD

Item 1 - 10 / 10
1